Avedro scores FDA advancement for eye disease treatment

Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. has been granted orphan drug designation by the U.S. Food and Drug Administration for its treatment of keratoconus, a degenerative eye disease found to be the leading cause of corneal transplants in the U.S.